IONS - アイオニス・ファ―マシュ―ティカルズ (Ionis Pharmaceuticals Inc.) アイオニス・ファ―マシュ―ティカルズ

 IONSのチャート


 IONSの企業情報

symbol IONS
会社名 Ionis Pharmaceuticals Inc (アイオニス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イオニス・ファーマシューティカルズ(Ionis Pharmaceuticals Inc.)(旧名:Isis Pharmaceuticals Inc.)はリボ核酸標的(RNA標的)薬の発見・開発会社である。同社はアンチセンス薬の発見・開発に焦点を当てる。同社のアンチセンス薬は、心血管、代謝、神経疾患を含む重症・希少疾患、及び癌等疾患の治療に使用される。Volanesorsenは、家族制カイロミクロン血症(FCS)と呼ばれる遺伝子疾患を持つ患者及び限局性脂肪異栄養症を持つ患者を含む高トリグリセリドレベルを有する患者の治療のための薬である。同社は、後期フェーズIII薬、nusinersen、volanesorsenとIONIS-TTRを市場に導入することに焦点を当てる。同社の脂質低下製品KYNAMRO(ミポメルセンナトリウム)注射液は、米国市場でホモ接合型家族性高コレステロール血症(HoFH)を持つ患者に使用される。同社の製品はまたAlicaforsen、IONIS-DMPK-2.5、PlazomicinとIONIS-GCGRが含まれる。  アイオニス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に治療用新化合物の発見・製造・販売に従事。同社製品には遺伝性高脂血症治療薬の「KYNAMRO」や、高トリグリセリド血症治療薬の「ISIS-APOCIIIRx」や「ISIS-FXIRx」がある。本社はカリフォルニア州サンディエゴ。   
本社所在地 2855 Gazelle Court Carlsbad CA 92010 USA
代表者氏名 Stanley T. Crooke スタンリーT.クルーク
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 760-931-9200
設立年月日 32509
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 547人
url www.ionispharma.com
nasdaq_url https://www.nasdaq.com/symbol/ions
adr_tso
EBITDA EBITDA(百万ドル) -32.05600
終値(lastsale) 44.96
時価総額(marketcap) 6171834858.72
時価総額 時価総額(百万ドル) 6203.408
売上高 売上高(百万ドル) 555.37600
企業価値(EV) 企業価値(EV)(百万ドル) 4848.796
当期純利益 当期純利益(百万ドル) 67.31500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ionis Pharmaceuticals Inc revenues increased 19% to $262.2M. Net loss increased from $2.2M to $41.8M. Revenues reflect Akcea Therapeutics segment increase from $11.8M to $35.4M. Higher net loss reflects Ionis core segment income decrease of 63% to $40.5M Akcea Therapeutics segment loss increase of 13% to $93.8M Elimination of Intercompany Activity segment loss totaling $379K vs. income of $60K.

 IONSのテクニカル分析


 IONSのニュース

   Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis  2021/03/01 12:05:00 PR Newswire
CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR), facilitates…
   Ionis reports fourth quarter and full year 2020 financial results and recent business achievements  2021/02/24 12:00:00 PR Newswire
CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "Last year, we laid out a bold new vision for the Company and took important steps towards our…
   Earnings Scheduled For February 24, 2021  2021/02/24 08:35:09 Benzinga
Companies Reporting Before The Bell • Pinnacle West Capital (NYSE: PNW ) is expected to report quarterly earnings at $0.04 per share on revenue of $715.74 million. • Itron (NASDAQ: ITRI ) is projected to report quarterly earnings at $0.30 per share on revenue of $569.75 million. • BGC Partners (NASDAQ: BGCP ) is expected to report quarterly earnings at $0.12 per share on revenue of $470.95 million. • Bausch Health Cos (NYSE: BHC ) is projected to report quarterly earnings at $1.12 per share on revenue of $2.17 billion. • Cheniere Energy Partners, LP Cheniere Energy Partners, LP Common Units (AMEX: CQP ) is expected to report quarterly earnings at $0.69 per share on revenue of $1.73 billion. • Casper Sleep (NYSE: CSPR ) is expected to report quarterly loss at $0.35 per share on revenue of $138.15 million. • Caesarstone (NASDAQ: CSTE ) is projected to report earnings for its fourth quarter. • China Yuchai Intl (NYSE: CYD ) is projected to report earnings for its fourth quarter. • Elanco Animal Health (NYSE: ELAN ) is estimated to report quarterly earnings at $0.
   Ionis to hold 2020 financial results webcast  2021/02/11 12:05:00 PR Newswire
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern…
   DelveInsight Analysts Expect Beta-Thalassemia Market Size to Expand at a CAGR of 16.3% During the Study Period (2017-2030) in the 6MM  2021/02/08 16:30:00 Benzinga
LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany , France , Italy , and Spain ) for the study period. The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market. Some of the key highlights from the Beta-Thalassemia Market Report: The Beta-Thalassemia market outlook appears to be ruled by the iron-chelating agents . Exjade is the first, once-daily oral iron chelator commercially available to treat chronic transfusional iron overload due to a wide range of underlying anemia. The Beta-Thalassemia market is witnessing an influx of gene therapies and gene-edited cell therapies to eradicate the lifetime burden of the disease.
   Ionis to hold 2020 financial results webcast  2021/02/11 12:05:00 PR Newswire
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern…
   DelveInsight Analysts Expect Beta-Thalassemia Market Size to Expand at a CAGR of 16.3% During the Study Period (2017-2030) in the 6MM  2021/02/08 16:30:00 Benzinga
LAS VEGAS , Feb. 8, 2021 /PRNewswire/ -- DelveInsight's Beta-Thalassemia Market report offers a holistic picture of the market landscape of the Beta Thalassemia key companies, emerging pipeline therapies, Beta-Thalassemia market share occupied by individual therapies, current and forecasted Beta-thal market share in the 6MM (the US, and EU5 (the UK, Germany , France , Italy , and Spain ) for the study period. The report highlights the drivers and constraints shaping the present Beta-Thalassemia Market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market. Some of the key highlights from the Beta-Thalassemia Market Report: The Beta-Thalassemia market outlook appears to be ruled by the iron-chelating agents . Exjade is the first, once-daily oral iron chelator commercially available to treat chronic transfusional iron overload due to a wide range of underlying anemia. The Beta-Thalassemia market is witnessing an influx of gene therapies and gene-edited cell therapies to eradicate the lifetime burden of the disease.
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.
   Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines  2021/01/05 12:00:00 Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. also participated in the ro
   Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines  2021/01/05 12:00:00 Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. also participated in the ro
   Amyotrophic Lateral Sclerosis (ALS) Market 2020-2027 Moving Towards Brighter Future | Major Giants – BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon  2020/12/14 15:55:14 OpenPR
In Amyotrophic Lateral Sclerosis (ALS) Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables,
   Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Sells $568,370.00 in Stock  2020/12/12 10:10:44 Watchlist News
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $51.67, for a total transaction of $568,370.00. Following the sale, the chairman now directly owns 2,021 shares of the company’s stock, valued at $104,425.07. The […]
   Global Cytomegalovirus Retinitis Market Growth Factors and Applications by 2027 with Top Key Players: Gilead Sciences, Inc., Hospira, Shire Plc, Auritec Pharmaceuticals Inc., Chimerix, Ionis Pharmaceuticals  2020/12/11 09:37:33 OpenPR
Data Bridge Market Research has recently added a concise research on the Cytomegalovirus Retinitis Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by
   Plasma Protease C1-inhibitor Treatment Market Research Scope Industry Chain Analysis & Opportunities 2018 to 2026 | CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc.  2020/12/11 07:41:08 OpenPR
The research report Plasma Protease C1-inhibitor Treatment Market Analysis 2020 provides an estimate of the market size from 2020 to 2026 in terms of value and volume. It also includes a full assessment of key market segments and Plasma Protease

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アイオニス・ファ―マシュ―ティカルズ IONS Ionis Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)